AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9789512 — intervention group
Group type: COMPARATOR
Intervention: Mock therapeutic touch
Number of subjects: 25
Study 9789512 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 25
Study 7658482 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3000 mg of calcium carbonate providing 1200 mg elemental calcium)
Number of subjects: 333
Study 7658482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 7658482 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 333
Study 2611171 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary surveillance
Number of subjects: 60
Study 2611171 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 60
Study 327092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonamide susceptibility testing using the disk-agar diffusion method
Number of subjects: 0
Study 31783762 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit program (TKR-H)
Number of subjects: 48
Study 31783762 — intervention group
Group type: COMPARATOR
Intervention: Non-home visit program (TKR)
Number of subjects: 48
Study 28222309 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-erlotinib-capecitabine (GEC)
Number of subjects: 120
Study 28222309 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-erlotinib (GE)
Number of subjects: 120
Study 28222309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rash (grade ≥1)
Number of subjects: 120
Study 26070976 — intervention group
Group type: EXPERIMENTAL
Intervention: PAG training (n=12)
Number of subjects: 23
Study 26070976 — intervention group
Group type: COMPARATOR
Intervention: Active control (n=11)
Number of subjects: 23
Study 23722054 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM levels at 70 and 75 years
Number of subjects: 1002
Study 23722054 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MR-proADM levels over time
Number of subjects: 1002
Study 23722054 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MR-proADM levels
Number of subjects: 1002
Study 21988265 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 21
Study 21988265 — intervention group
Group type: COMPARATOR
Intervention: SHAM device
Number of subjects: 21
Study 19232934 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg/kg
Number of subjects: 115
Study 19232934 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 115
Study 19232934 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 115
Study 17825405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix A (sodium benzoate and artificial food colour mix A)
Number of subjects: 297
Study 17825405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix B (sodium benzoate and artificial food colour mix B)
Number of subjects: 297
Study 17825405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 15313860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone sodium phosphate (1 mg/kg)
Number of subjects: 219
Study 15313860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 11576055 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg bolus before morphine
Number of subjects: 40
Study 11576055 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg i.v. without propofol
Number of subjects: 40
Study 11576055 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.3 mg/kg bolus followed by 1 mg/kg/h infusion during the study
Number of subjects: 40
Study 9688371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU i.m. HCG
Number of subjects: 18
Study 9688371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU i.m. HCG
Number of subjects: 18
Study 9688371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU s.c. HCG
Number of subjects: 18
Study 8020523 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol
Number of subjects: 100
Study 8020523 — intervention group
Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 100
Study 2616932 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A followed by Treatment B
Number of subjects: 0
Study 2616932 — intervention group
Group type: COMPARATOR
Intervention: Treatment B followed by Treatment A
Number of subjects: 0
Study 319967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide 9.6 mg
Number of subjects: 0
Study 319967 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine 12.5 mg
Number of subjects: 0
Study 31521831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks
Number of subjects: 1083
Study 31521831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study 29571932 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐FiO2 with target range 86%‐94%
Number of subjects: 41
Study 29571932 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐FiO2 with target range 88%‐92%
Number of subjects: 41
Study 29571932 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐FiO2 with target range 89%‐91%
Number of subjects: 41
Study 26812613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaerobics program
Number of subjects: 36
Study 26812613 — intervention group
Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 36
Study 26812613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 26812613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaerobics group
Number of subjects: 36
Study 23661583 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters after one cycle of neoadjuvant chemotherapy
Number of subjects: 28
Study 21126918 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual face-to-face education and counseling intervention (45 min session)
Number of subjects: 2597
Study 21126918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2597
Study 20040056 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) using student-teachers (STs) with limited training
Number of subjects: 151
Study 20040056 — intervention group
Group type: COMPARATOR
Intervention: Staff-led group (SG) taught by ultrasound-experienced doctors
Number of subjects: 151
Study 20040056 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-teachers (STs)
Number of subjects: 151
Study 18591555 — intervention group
Group type: COMPARATOR
Intervention: Topotecan monotherapy 1.25 mg/m(2)/d
Number of subjects: 502
Study 18591555 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.0 mg/m(2) plus oral etoposide 50 mg/d
Number of subjects: 502
Study 18591555 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 0.5 mg/m(2)/d plus gemcitabine 800 mg/m(2) on day 1 and 600 mg/m(2) on day 8 every 3 weeks
Number of subjects: 502
Study 15982747 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day (increased to 20 mg/day after 4 weeks)
Number of subjects: 850
Study 15982747 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 850
Study 15982747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 12162936 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 12162936 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0
Study 12162936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACE inhibitor plus ARB therapy
Number of subjects: 0
Study 10392386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at the right atrium (A)
Number of subjects: 37
Study 10392386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at the RV paraseptal area (B), RV outflow tract (C), LV apex (D)
Number of subjects: 37
Study 10392386 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite pacing (combination of sites)
Number of subjects: 37
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents with antiplatelet drugs (250 mg ticlopidine and 100 mg aspirin)
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase I
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase II
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase III
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase IV
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (all phases combined)
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase I)
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase II)
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase III)
Number of subjects: 207
Study 8565157 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase IV)
Number of subjects: 207
Study 1756790 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line visual feedback
Number of subjects: 0
Study 1756790 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 0
Study 1756790 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly ordered trials with visual feedback
Number of subjects: 0
Study 1756790 — intervention group
Group type: COMPARATOR
Intervention: Separate blocks of trials with feedback and no-feedback
Number of subjects: 0
Study 7051913 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of elemental zinc as zinc acetate (10 patients)
Number of subjects: 20
Study 7051913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 patients)
Number of subjects: 20
Study 31515716 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with preschool-onset depression
Number of subjects: 183
Study 31515716 — intervention group
Group type: COMPARATOR
Intervention: Healthy group of young children
Number of subjects: 183
Study 27494705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy
Number of subjects: 41
Study 30025257 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineering instructions
Number of subjects: 64
Study 30025257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both engineering and transfer instructions
Number of subjects: 64
Study 30025257 — intervention group
Group type: COMPARATOR
Intervention: Transfer instructions
Number of subjects: 64
Study 30025257 — intervention group
Group type: COMPARATOR
Intervention: No instructions
Number of subjects: 64
Study 25826291 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 0
Study 25826291 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet
Number of subjects: 0
Study 25826291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary advice delivery models
Number of subjects: 0
Study 24868024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg once per day plus paclitaxel 80 mg/m² once per week
Number of subjects: 261
Study 24868024 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 261
Study 24868024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 261
Study 23286539 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (FS)
Number of subjects: 60
Study 23286539 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 60
Study 20015219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent interleukin-2 (IL-2) plus combination antiretroviral therapy (cART)
Number of subjects: 54
Study 20015219 — intervention group
Group type: COMPARATOR
Intervention: Combination antiretroviral therapy (cART) only
Number of subjects: 54
Study 17875076 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/day) for 20 days
Number of subjects: 61
Study 17875076 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 20 days
Number of subjects: 61
Study 16132897 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral lipid‐based nutrition (L group)
Number of subjects: 33
Study 16132897 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral glucose‐based nutrition (G group)
Number of subjects: 33
Study 12177267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous total hip arthroplasty
Number of subjects: 156
Study 12177267 — intervention group
Group type: COMPARATOR
Intervention: Unilateral total hip arthroplasty
Number of subjects: 156
Study 12177267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented stem
Number of subjects: 156
Study 12177267 — intervention group
Group type: COMPARATOR
Intervention: Cementless stem
Number of subjects: 156
Study 12177267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow-cell embolization
Number of subjects: 156
Study 10464829 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler 12 micrograms bd
Number of subjects: 469
Study 10464829 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol Accuhaler 50 micrograms bd
Number of subjects: 469
Study 10464829 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler
Number of subjects: 469
Study 7817481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (43 weeks, range 3 to 90 weeks)
Number of subjects: 36
Study 7817481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (during instillations)
Number of subjects: 36
Study 7817481 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-mitomycin C (after prophylaxis)
Number of subjects: 36
Study 2112080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungarian-made levonorgestrel tablets (0.75 mg)
Number of subjects: 0
Study 2112080 — intervention group
Group type: COMPARATOR
Intervention: Chinese-made levonorgestrel tablets (0.75 mg)
Number of subjects: 0
Study 7323106 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18
Study 7323106 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18
Study 7323106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1080 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18
Study 7323106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1440 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18
Study 7323106 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 18
Study 31426731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 6 months
Number of subjects: 3127
Study 31426731 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 3127
Study 31426731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 3127
Study 31426731 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >70 years
Number of subjects: 3127
Study 31426731 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3127
Study 29079602 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-provided self-management intervention
Number of subjects: 440
Study 29079602 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual supplemented by a booklet on self-management
Number of subjects: 440
Study 26475266 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK-100STP 120 μg/day
Number of subjects: 112
Study 26475266 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK-100STP 240 μg/day
Number of subjects: 112
Study 26475266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 23706123 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 μg/kg
Number of subjects: 90
Study 23706123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21327422 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal oral solution (600 mg)
Number of subjects: 60
Study 21327422 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal capsules (600 mg)
Number of subjects: 60
Study 21327422 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 19736358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducational psychotherapy plus treatment as usual
Number of subjects: 165
Study 19736358 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC) plus treatment as usual
Number of subjects: 165
Study 20210680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice daily
Number of subjects: 35
Study 20210680 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice daily
Number of subjects: 35
Study 20210680 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy (LSS) combining C(max) and C(12h) after EC-MPS administration
Number of subjects: 35
Study 20210680 — intervention group
Group type: EXPERIMENTAL
Intervention: C(12h) after MMF ingestion
Number of subjects: 35
Study 15565433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (700 kcal/day deficit)
Number of subjects: 17
Study 15565433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-CHO/normal-calorie diet
Number of subjects: 17
Study 15565433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-CHO/low-calorie diet
Number of subjects: 17
Study 15565433 — intervention group
Group type: COMPARATOR
Intervention: Normal-calorie diet (2,000-2,800 kcal/day)
Number of subjects: 17
Study 11897543 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ritanserin
Number of subjects: 8
Study 11897543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10437612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intra-arterial chemotherapy (mitomycin C 8 mg/m2 on day 1 and 5-fluorouracil 800 mg/m2 on days 1-5 for four courses at 4-week intervals) in group A (14 patients)
Number of subjects: 42
Study 10437612 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, 16 patients)
Number of subjects: 42
Study 10437612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes A/B patients (12 patients)
Number of subjects: 42
Study 10437612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes C patients (30 patients)
Number of subjects: 42
Study 10437612 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall probability of remaining free of recurrent disease
Number of subjects: 42
Study 7777112 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive uremic patients
Number of subjects: 30
Study 7777112 — intervention group
Group type: COMPARATOR
Intervention: Normotensive uremic patients
Number of subjects: 30
Study 7777112 — intervention group
Group type: COMPARATOR
Intervention: Uremic patients (both hypertensive and normotensive)
Number of subjects: 30
Study 7777112 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study 19256155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (SB) 5.6 g/day
Number of subjects: 27
Study 19256155 — intervention group
Group type: COMPARATOR
Intervention: Lactitol (LA) 29 g/day
Number of subjects: 27
Study 436049 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape educational program
Number of subjects: 62
Study 436049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no videotape)
Number of subjects: 62
Study 12734151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg) three times a day for two weeks before surgery
Number of subjects: 50
Study 12734151 — intervention group
Group type: COMPARATOR
Intervention: Placebo drug three times a day for two weeks before surgery
Number of subjects: 50
Study 29737805 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement containing Lactobacillus acidophilus LA‐5, Bifidobacterium BB‐12, Streptococcus Thermophilus STY‐31, and Lactobacillus delbrueckii bulgaricus LBY‐27
Number of subjects: 64
Study 29737805 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 64
Study 29737805 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 64
Study 27689551 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 minutes) + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Number of subjects: 26
Study 27689551 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Number of subjects: 26
Study 24429175 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 237
Study 24429175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 22227576 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS plus therapy
Number of subjects: 23
Study 22227576 — intervention group
Group type: COMPARATOR
Intervention: Therapy only
Number of subjects: 23
Study 22227576 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS only
Number of subjects: 23
Study 20357371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 2.0 units/kg
Number of subjects: 20
Study 20357371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 1.5 units/kg
Number of subjects: 20
Study 20357371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 1.0 units/kg
Number of subjects: 20
Study 20357371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 0.5 units/kg
Number of subjects: 20
Study 20357371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (all doses)
Number of subjects: 20
Study 17934975 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 or 160 mg aspirin daily
Number of subjects: 289
Study 17934975 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 289
Study 16043735 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg OD) + Metformin (1.5-3.0 mg/day)
Number of subjects: 57